Overview

Simvastatin in Overcoming Chemotherapy Resistance in Patients With Relapsed or Refractory Multiple Myeloma

Status:
Withdrawn
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
This pilot clinical trial studies how well simvastatin works in overcoming chemotherapy resistance in patients with multiple myeloma that has come back or does not respond to treatment. Simvastatin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Phase:
Early Phase 1
Details
Lead Sponsor:
Wake Forest University Health Sciences
Collaborator:
National Cancer Institute (NCI)
Treatments:
Simvastatin